We read, with great interest, the articles and
the editorial in your November 13, 1995, issue of the Archives.1-3 Like so many in your
readership, we use a large volume of calcium antagonists in the treatment of our hypertensive patients, particularly those with arrhythmias and angina. We have also
listened to Furberg and Psaty3 at various meetings.
One issue that all the authors1-3 should have addressed in more detail in their articles relates to the dose-response differences of these agents. The Treatment of
Mild Hypertension Study4 is alluded to by Epstein2 in regard to comparisons of different antihypertensive agents.
However, as the Treatment of Mild Hypertension Study
demonstrated, low doses of various classes of pharmacologic agents, as opposed to higher doses, may have differing physiologic effects. Furberg,5 himself, has stated
that dose-response differences represent one issue that
directed him to the potential problems associated with
Bloomfield RL, Miller HS, Pedley CF, Colflesh MJ, Novikov S. A Low-Dose Perspective on the Calcium Antagonist Controversy. Arch Intern Med. 1996;156(10):1115–1116. doi:10.1001/archinte.1996.00040041115017
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: